Join our mailing list so you can receive valuable information and be
notified as soon as Flibanserin becomes available!
Don’t miss out! Click here.
Girosa is the thought to be proposed name of the Flibanserin drug, currently under clinical test by the Boehringer Ingelheim GmbH German pharmaceutical company. The product line is surrounded by great secrecy and little information is to be found on it. There is a very good reason for this secrecy, as it is anticipated that the market for this so-called female Viagra has a value of roughly $30 million dollars sales per year. The drug has been development and test for some years now, and it has been generally referred to as Flibanserin. However, according to some rumors, the official name of the product will be Girosa after its acceptance for us in the United States.
What is this drug?
Basically, Girosa is a non-hormonal drug consisting of dopamine or D4 cereptors and serotonin receptors also known as 5-HT. Paradoxically, it has been originally developed as an antidepressant, but it seems that when improvements in female sexual desire were reported, the company saw the opportunity for much higher profits in this specific area compared to the much crowded mood enhancer segment. This drug increases the dopamine level in the female body, which is to a certain degree responsible for libido and arousal and thus it might be helpful in pre-menopausal Hypo Sexual Desire Disorder – HSDD, or Female Sexual Dysfunction – FSD. Well, in any case that is the declared target market and objective of the end product.
Interestingly, Boehringer Ingelheim GmbH is not fully sure about how the positive effect on sexual desire arises from Flibanserin, but they are reposting positive results from all their four clinical tests that have involved more than 5,000 women in over 220 clinics across the world. As BioSante is planning to get FDA approval for LibiGel within the next 18 months, Boehringer is also expecting to have FDA approval for medical use in the United States in the near future. Targeting the women Viagra market, it is evident how a multi-million dollar industry for men can have a trickle effect on the market for women, especially if we take in consideration the estimation of scientist and doctors that around 40% of women in the United States experience some symptom of HSDD or FSD.
Posted in
[...] is designed to treat the decreased sexual desire of women. Flibanserin, sometimes known as either Girosa or ‘female Viagra’ was rejected 10 votes to 1 by an FDA Advisory Panel who claimed that [...]